Skip to content
Quebec News Tribune – Lifestyle
Author:
Telix Pharmaceuticals Limited
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
September 1, 2026
Telix Appoints David Gill as Chair
August 31, 2026
Telix to Host R&D Day in New York City on September 22, 2026
August 5, 2026
Telix H1 2026 Results: Investor Webcast Notification
July 30, 2026
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 21, 2026
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
July 20, 2026
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
July 15, 2026
FDA Alignment to Advance ProstACT Global Phase 3 Trial
July 1, 2026
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
June 22, 2026
1
2
3
Next Page
→